Use of compounds in combination with gamma-irradiation for the treatment of cancer
OwnerRickard Glas, Hong Xuinventors
Life of this patent
Estimating the term…
Abstract
TPP II (tripeptidyl peptidase inhibitors are useful in enhancing the efficacy of gamma-irradiation cancer therapy or increasing the in vivo gamma-irradiation susceptibility of tumour cells. Suitable compounds comprise tripeptide compounds of general formula RN1RN2N-A1-A2-A3-CO—RC1 wherein RN1, RN2, A1, A2, A3 and RC1 are as defined herein, and which include for example the tripeptide sequences GLA and GPG. Complete in vivo tumor regression in mice injected with TPPII inhibitors is observed, during treatment in combination with gamma-irradiation.
Claims37
A method of enhancing the efficacy of gamma-irradiation cancer therapy or increasing the in vivo gamma-irradiation susceptibility of tumour cells comprising administering to a patient in need thereof a therapeutically effective amount of a TPP II inhibitor compound.
32-36. (canceled)
A method for identifying a compound suitable for enhancing the efficacy of gamma-irradiation cancer therapy or increasing the in vivo gamma-irradiation susceptibility of tumour cells comprising contacting TPP II with a compound to be screened, and identifying whether the compound inhibits the activity of TPP II.
39-42. (canceled)
44-45. (canceled)
Dependencies are inferred from the claim text.